← Back

Jiangzhong Pharmaceutical Co Ltd

22.53+2.7%1Y · CNY

China Resources Jiangzhong Pharmaceutical Co., Ltd. manufactures pharmaceutical products in China. Its offerings include OTC products such as stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, fritillaria and loquat capsules, bezoar and snake gallbladder fritillaria liquid, and compound gold melon seed. The company also provides health consumer products in areas such as nourishment, tonics, rehabilitation nutrition, gastrointestinal health, and liver health, as well as prescription drugs including traditional Chinese medicines (Shenbao capsules, Paishi granules, Huangba Shengmai drink, Bazhen Yimu capsules), chemical medicines (lumbrokinase enteric-coated capsules, Rabeprazole sodium enteric-coated tablets, chloroprocaine hydrochloride), and medicinal materials such as codonopsis pilosula. Formerly known as Jiang Zhong Pharmaceutical Co., Ltd., it changed its name to China Resources Jiangzhong Pharmaceutical Co., Ltd. in January 2025; it was founded in 1996 and is headquartered in Nanchang, China.

Country
Price · split & dividend adjusted
News & notes moving 600750.CG
Macao SAR ChinaChina
600750.CG▲

China Resources Jiangzhong's Jianwei Xiaoshi Tablets Obtain Macau Chinese Patent Medicine Registration Certificate

China Resources Jiangzhong announced that the company recently received the Chinese Patent Medicine Registration Certificate for Jianwei Xiaoshi Tablets, Jiangzhong brand, approved and issued by the Pharmaceutical Administration Bureau of the Macau Special Administrative Region Government. The dosage form is tablets, and the category is over-the-counter Chinese patent medicine. The product's functions and indications are to strengthen the stomach and promote digestion, used for food stagnation and indigestion caused by weakness of the spleen and stomach. The company stated that after obtaining this certificate, the product can be sold in Macau, which is conducive to expanding overseas market business and enhancing brand influence and market competitiveness. However, the company also pointed out that its internationalization business is still in the exploratory stage and is not expected to have a material impact on recent operating performance. Drug sales are subject to uncertainties due to factors such as the market environment and industry policies.
Jiangzhong Pha… ▲
600750.CG · Regulation · Positive Obtained Macau Chinese Patent Medicine Registration Certificate for Jianwei Xiaoshi Tablets, allowing sales in Macau and expanding overseas market business.
Read original ↗
Jiemian·26dRead more →
China
600750.CG▼2

China Resources Jiangzhong first-half net profit 491 million yuan, plans 5 yuan dividend per 10 shares

China Resources Jiangzhong disclosed its 2026 semi-annual report. In the first half, total operating revenue was 1.932 billion yuan, down 9.75 percent year on year. Net profit attributable to the parent was 491 million yuan, down 5.92 percent. Non-GAAP net profit was 470 million yuan, down 2.59 percent. The company plans a cash dividend of 5 yuan per 10 shares, tax included. Net cash flow from operating activities was 696 million yuan, up 6.80 percent year on year. Basic earnings per share were 0.78 yuan, and the weighted average return on equity was 11.51 percent.
Jiangzhong Pha… ▼
600750.CG · Capital · Negative First-half net profit fell 5.92% year on year, with revenue down 9.75%.
Read original ↗
中国证券报·45dRead more →
China
600750.CG▼

China Resources Jiangzhong's first-half net profit attributable to parent was 491 million yuan, down 5.9% year on year

China Resources Jiangzhong released its 2026 interim report. Net profit attributable to the parent in the first half was 491 million yuan, down 5.9% year on year. Operating revenue was 1.932 billion yuan, down 9.8% year on year. Net profit attributable to the parent after deducting non-recurring items was 470 million yuan, down 2.6% year on year. Net operating cash flow was 696 million yuan, up 6.8% year on year. Second-quarter operating revenue was 896 million yuan, down 6.4% year on year, and net profit attributable to the parent was 203 million yuan, down 14.3% year on year. The company said its main business has not undergone major changes, but revenue from some businesses such as prescription drugs declined due to the impact of centralized procurement policies and intensifying market competition.
Jiangzhong Pha… ▼
600750.CG · Capital · Negative First-half net profit fell 5.9% and revenue dropped 9.8% due to centralized procurement and competition.
Read original ↗
财中社·46dRead more →
China
600750.CG▲

China Resources Jiangzhong Plans Cash Dividend of 5 Yuan per 10 Shares

China Resources Jiangzhong announced plans to distribute a cash dividend of 5 yuan per 10 shares, including tax, to all shareholders, with an estimated total payout of 318 million yuan. In the first half of 2026, the company achieved revenue of 1.932 billion yuan and net profit attributable to the parent of 491 million yuan.
Jiangzhong Pha… ▲
600750.CG · Capital · Positive Announced cash dividend of 5 yuan per 10 shares, totaling 318 million yuan, with solid H1 2026 results.
Read original ↗
财中社·46dRead more →
China
600750.CG

China Resources Jiangzhong lists Sanghai Pharmaceutical 51% stake for third time, reserve price down about 41% from last year

China Resources Jiangzhong plans to list its roughly 51% stake in Jiangxi Nanchang Sanghai Pharmaceutical through the Shanghai United Assets and Equity Exchange for the third time, with a reserve price of 27.8107 million yuan, a discount of about 41% from the 47.4498 million yuan reserve price for the same proportional stake last year. In April 2025, the full 100% equity of Sanghai Pharmaceutical was first listed with a reserve price of 99.0208 million yuan. In June of the same year, the price was lowered to 93.0308 million yuan for a second listing, but the process ended without attracting any intended transferees. China Resources Jiangzhong responded that this disposal is conducive to optimizing the asset structure and resource allocation efficiency, and will not have a material impact on its main business. Sanghai Pharmaceutical's performance has continued to decline in recent years, with revenue of only 3.51 million yuan and net profit of 370,000 yuan in 2025. In the same period, China Resources Jiangzhong achieved net profit attributable to the parent of 907 million yuan, up 15.03% year-on-year, but revenue from its core over-the-counter segment was 2.992 billion yuan, down 8.39% year-on-year, marking the first annual decline since 2016. Sales of its Jianwei Xiaoshi tablets reached 165 million boxes, a decrease of 2.36% year-on-year.
Jiangzhong Pha…
江西南昌桑海制药有限责任公司 (Jiangxi Nanchang Sanghai Pharmaceutical Co., Ltd.) · Capital · Negative Stake listed for sale at a 41% discount, with declining performance and no buyers attracted previously.
600750.CG · Capital · Neutral Disposal of 51% stake in Sanghai Pharmaceutical at a lower price, but stated no material impact on main business; core OTC revenue declined.
Read original ↗
红星资本局·55dRead more →
600750.CG▲

State Council Approves Traditional Chinese Medicine 15th Five-Year Plan, Igniting TCM Sector; Longshen Rongfa Hits 20% Daily Limit Up

The State Council has approved in principle the Traditional Chinese Medicine Revitalization and Development 15th Five-Year Plan, igniting the TCM sector. On July 13, Longshen Rongfa hit the 20 percent daily limit up, Shanghai Kaibao and Biotech Valley surged over 10 percent, Tianmu Pharmaceutical hit the daily limit up, and many other stocks rose in sympathy. CITIC Securities believes that the cliff-like drop in upstream precious medicinal material prices has shed the cost burden, the midstream destocking cycle is nearing its end, and cost savings will flow through to the income statement. The current moment is the optimal window for contrarian positioning in the profit recovery inflection point of the TCM OTC sector. China Post Securities noted that branded TCM companies have stable cash flows, and high-dividend TCM firms are trading at historically reasonable or low valuations, offering allocation appeal in a low-interest-rate environment. It suggests paying attention to names such as Dong-E-E-Jiao, Jumpcan Pharmaceutical, and China Resources Jiangzhong.
Gansu Longshen… ▲Shan Dong Dong… ▲Hubei Jumpcan… ▲Jiangzhong Pha… ▲Shanghai Kaiba… ▲Hangzhou TianM… ▲
300534.CS · Regulation · Positive State Council approval of TCM 15th Five-Year Plan directly benefits Longshen Rongfa as a TCM company, driving its 20% limit-up.
云南生物谷药业股份有限公司 (Yunnan Biovalley Pharmaceutical Co., Ltd.) · Regulation · Positive State Council approval of TCM 15th Five-Year Plan boosts Biotech Valley, a TCM firm, leading to over 10% surge.
000423.CS · Demand · Positive Dong-E-E-Jiao mentioned by analyst as a high-dividend TCM firm with allocation appeal in low-rate environment.
600566.CG · Demand · Positive State Council approval of TCM 15th Five-Year Plan boosts sector demand; analyst notes high-dividend TCM firms like Jumpcan have allocation appeal.
600750.CG · Demand · Positive China Resources Jiangzhong mentioned by analyst as a high-dividend TCM firm with allocation appeal in low-rate environment.
300039.CS · Demand · Positive Shanghai Kaibao surged over 10% on sector rally driven by State Council plan approval.
Read original ↗
21世纪经济·85dRead more →
© 2026 MarketIVAsset